Table 4. Comparison of Area under the Receiver Operating Characteristics Curves (AUROC) for survival endpoints, between FibroTest, ActiTest, ALT and viral load. N = 1074.

Marker	Number of patients	Survival without HBV complications		Survival without HBV death		Overall Survival
		AUROC	95% CI	AUROC	95% CI	AUROC	95% CI
FibroTest	1074	0.89	0.84–0.93c	0.95	0.91–0.97 d	0.94	0.89–96e
Non-treated	428	0.99	0.89–0.90	0.99	0.96–0.99	0.99	0.89–0.99
Treated	646	0.82	0.75–0.88	0.90	0.84–0.94	0.89	0.83–0.93
ActiTest	1074	0.77	0.69–0.83	0.87	0.79–0.92	0.81	0.72–0.87
Non-treated	428	0.86	0.58–0.96	0.91	0.57–0.98	0.86	0.58–0.96
Treated	646	0.70	0.61–0.77	0.83	0.73–0.89	0.76	0.65–0.84
ALT	1074	0.53	0.46–0.60	0.55	0.44–0.65	0.55	0.46–0.63
Non-treated	428	0.54	0.46–0.62	0.57	0.48–0.64	0.54	0.46–0.62
Treated	646	0.51	0.44–0.58	0.54	0.42–0.64	0.53	0.44–0.62
Viral load	1074	0.64	0.55–0.71	0.67	0.54–0.76	0.63	0.52–0.72
Non-treated	428	0.57	0.30–0.76	0.62	0.28–0.82	0.57	0.29–0.76
Treated	646	0.61	0.51–0.69	0.65	0.51–0.76	0.61	0.49–0.71

^cFibroTest AUROC greater than that with ActiTest (p<0.001), ALT (p<0.001), Viral load (p<0.001).

^dFibroTest AUROC greater than that with ActiTest (p = 0.0009), ALT (p = <0.001), Viral load (p<0.001).

^eFibroTest AUROC greater than that with ActiTest (p<0.001), ALT (p<0.001), Viral load (p<0.001).